


衛生署藥物辦公室
藥物註冊及進出口管制部

香港九龍彌敦道街 382 號公共衛生檢測中心二樓



DEPARTMENT OF HEALTH
DRUG OFFICE
DRUG REGISTRATION AND
IMPORT/EXPORT CONTROL DIVISION
3/F., Public Health Laboratory Centre,
382 Nam Cheong Street, Kowloon, Hong Kong

電話號碼 Tel. No.: 2319 8458
詢問處 Enquiries (852) 2319 8458
傳真號碼 Faxline No. (852) 2803 4962
本署編號 OUR REF.: DH DO PRIE/7-30/15

BY FAX

4 July 2013

(來函請註明此檔案號碼)
(IN REPLY PLEASE QUOTE THIS FILE REF.)

Dr. Donald LI
President
Hong Kong Academy of Medicine
(Fax Number: 2505 5577)

Dear Dr. LI,

Olmesartan Medoxomil – Intestinal Problems (Sprue-Like Enteropathy)

Your attention is drawn to the US Food and Drug Administration's (FDA) announcement with respect to olmesartan medoxomil can cause intestinal problems known as sprue-like enteropathy. Symptoms of sprue-like enteropathy include severe, chronic diarrhea with substantial weight loss and they may develop months to years after starting olmesartan.

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) approved for the treatment of high blood pressure, alone or with other antihypertensive agents, and is one of eight marketed ARB drugs in the US. Sprue-like enteropathy has not been detected with ARB drugs other than olmesartan. FDA had approved changes to the labels of the products containing olmesartan to include this concern.

Healthcare professionals are advised to ask their patients to report if they develop severe, chronic diarrhea with substantial weight loss while taking an olmesartan-containing product, even if it takes months to years for symptoms to develop. Besides, if a patient develops these symptoms during treatment with olmesartan, other etiologies, such as celiac disease, should be investigated. If no other etiology is identified, olmesartan should be discontinued and another antihypertensive treatment started.

Please refer to FDA's website for details:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm359528.htm>

In Hong Kong, there are 14 registered pharmaceutical products containing olmesartan medoxomil. They are prescription-only medicines and indicated for the treatment of essential hypertension. So far, the Department of Health has not received any adverse drug reaction report in relation to the drug. In view of FDA's recommendation, the matter will be discussed in the meeting of the Registration Committee of the Pharmacy and Poisons Board. Healthcare professionals are advised to balance the risk of possible adverse effects against the benefit of treatment.

Please encourage your members to report any adverse events caused by the drugs to the Pharmacovigilance Unit of Department of Health (tel. no.: 2319 2920, fax: 2186 9845 or email: adr@dh.gov.hk). For details, please refer to the website at Drug Office under "ADR reporting": <http://www.drugoffice.gov.hk/adr.html>. You may wish to visit the Drug Office's website for subscription and browsing of "Drug News" which is a monthly drug safety digest of drug safety news and information issued by Drug Office.

Yours sincerely,

(Ms. Pamela LI)

for Assistant Director (Drug)

We are committed to providing quality client-oriented service